Lead oncology asset ivonescimab showed strong PFS results in Phase III trials, but FDA approval hinges on OS significance. Net loss narrowed year-over-year, but liquidity is insufficient for the next 12 months, raising going concern risk.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.